FFAI Rockets 50% After Analyst Hike; SLNO, SPIR Lead Healthcare & Industrials Higher
FFAI surged 50% to $0.33 after analysts revised next-year EPS estimates up 12.9 percentage points to 63.2%, marking the biggest single-stock move in today's screening data. SLNO followed with a 33% rally to $52.51 as EPS estimates climbed 9.5pp to 68.7%, while SPIR added 28.7% to $20.48 after a near-doubling of its EPS growth forecast from 58.9% to 95.6%. Healthcare names INBX and biotech SLNO broadly outperformed, suggesting positive sentiment in speculative growth names.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| FFAI | Consumer Cyclical | 2026-04-06 | +12.9pp | +50.0% |
| SLNO | Healthcare | 2026-04-05 | +9.5pp | +33.0% |
| SPIR | Industrials | 2026-04-05 | +36.7pp | +28.7% |
| IQST | Communication Services | 2026-04-06 | N/A | +17.6% |
| INBX | Healthcare | 2026-04-05 | +17.8pp | +16.9% |
FFAI — Faraday Future Intelligent Electric Inc
FFAI's 50% price surge from $0.22 to $0.33 over four sessions reflects a sharp re-rating as next-year EPS estimates jumped 12.9 percentage points to 63.2%, implying a dramatic improvement in expected profitability. The EV maker appears to have attracted buying interest as the revised estimates signal a potential path toward positive earnings, which is critical for a penny-stock with historically thin fundamentals. With no recent news, the move appears purely estimate-driven — traders are front-running what analysts now view as substantially better earnings prospects. The 50% gain in four days suggests thin trading conditions amplified the response to the revised estimates.
View screener snapshot from 2026-04-06 →SLNO — Soleno Therapeutics Inc
SLNO climbed 33% to $52.51 after next-year EPS estimates rose 9.5pp to 68.7%, indicating analysts are growing more confident in Soleno's earnings trajectory. The 33% price gain in five sessions outpaced the 9.5pp estimate revision, suggesting investors are pricing in a more aggressive earnings recovery scenario. Healthcare's risk-on tone in recent sessions likely reinforced the move, as SLNO's therapeutics focus attracts momentum buyers when sector sentiment improves. Without specific news, the primary driver appears to be the continued upward EPS revision trend signaling fundamental strengthening.
View screener snapshot from 2026-04-05 →SPIR — Spire Global Inc
SPIR's 28.7% jump to $20.48 coincided with the most dramatic EPS revision in today's data — a 36.7 percentage point surge from 58.9% to 95.6% growth expectations. The near-doubling of expected EPS growth suggests analysts are incorporating significantly higher revenue or margin projections for Spire's satellite and data services. Industrial space plays often react sharply when earnings estimates normalize, as valuation multiples compress when growth visibility improves. The magnitude of the revision (36.7pp) explaining a 28.7% price move indicates the market had been pricing in much lower earnings potential prior to the estimate change.
View screener snapshot from 2026-04-05 →IQST — iQSTEL Inc
IQST gained 17.6% to $1.94 as next-year EPS growth expectations hit 81.6%, the highest growth rate among today's group. While the screener didn't capture a revision delta (only the current figure), the 81.6% growth projection itself signals substantial analyst optimism around iQSTEL's telecom and technology services. Communication services stocks with high growth expectations often attract speculative buying, and the 17.6% response over four sessions indicates the market is treating this EPS profile as compelling for a sub-$2 stock. Without a prior comparison point, the move likely reflects initial recognition of strong earnings growth potential.
View screener snapshot from 2026-04-06 →INBX — Inhibrx Biosciences Inc
INBX rose 16.9% to $74.28 as analysts revised next-year EPS estimates up 17.8 percentage points to 48.9%, the second-largest revision in today's healthcare cohort. The biotech space has seen elevated interest in names with improving earnings visibility, and Inhibrx's 48.9% growth target appears to be drawing buyer interest. The 16.9% price gain tracking closely to the 17.8pp revision suggests the market is efficiently incorporating the updated estimates rather than over-reacting. Healthcare broadly has shown strength in recent sessions, providing a favorable backdrop for INBX's earnings-driven rally.
View screener snapshot from 2026-04-05 →Today's screening results indicate the market is actively re-pricing small-cap growth stocks with improving earnings profiles, particularly in healthcare and speculative industrials, suggesting risk appetite remains elevated for fundamentally re-rated names.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →